Kymera Investor Presentation Deck

KYMERA Recognized leader in Targeted Protein Degradation (TPD) Building a fully-integrated, global biotech company Focusing on I/I and some areas of Oncology, with disease- agnostic potential Accelerating forward integration through key strategic partnerships KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC. ● Overview Focused on unlocking high value, undrugged targets using TPD Advanced four programs to clinical stage to date, first degrader program in I/I with IRAK4 demonstrating degrader differentiation Demonstrated fidelity of translation of PK, PD and safety across four clinical programs in both immunology and oncology Demonstrated clinical activity in three programs in immunology and oncology Initiated two Phase 2 trials for KT-474/SAR444656, in potential blockbuster indications (HS & AD) with Sanofi Highly productive discovery engine delivering multiple INDs/year with expanding focus in I/I Well-capitalized with $435m of cash as of September 30, 2023, enabling expansion of clinical impact into areas with large clinical and commercial opportunities PAGE 3

View entire presentation